Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Oncology Briefing™: Exploring BRAF/MEK Inhibitors for the Treatment of NSCLC in Multiple Lines of Care

Release Date: January 31, 2018
Expiration Date: January 31, 2019
Media: Internet - based


Activity Overview

Oncology Briefing™ is an online interactive monograph that will provide an overview of recent data regarding emerging and novel treatment strategies for non-small cell lung cancer (NSCLC) with BRAF/MEK mutations. This format includes a brief presentation of clinical science and features a national thought leader, David R. Gandara, MD, who interprets it to provide key take-home points and clinical pearls for practice that will place the content into important perspective. Audio sidebars and tables provide supporting evidence.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, "Educational Content/Audio Files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational initiative is directed toward oncology healthcare professionals who treat patients with lung cancer, including medical oncologists, radiology oncologists, and surgical oncologists. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with lung cancers are also invited to participate.

Learning Objectives

Upon completion of this activity, you should be better able to:

  • Outline the rationale for BRAF mutations as targets for BRAF/MEK inhibitors in NSCLC and genotyping options to identify patients who may benefit from personalized approaches
  • Apply key evidence concerning BRAF/MEK to inform clinical decision making in the treatment of BRAF mutation‒positive NSCLC
  • Describe treatment-related toxicities associates with strategies used to manage patients with BRAF/MEK mutation‒positive NSCLC

Faculty, Staff, and Planners' Disclosures


David R. Gandara, MD 
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosure: Disclosure: Consultant: Novartis.

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By